Exicure, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for XCUR, updated each market day.
XCUR AI Sentiment
AI sees no strong directional signal for Exicure, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Exicure, Inc. Common Stock
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Sector
Exchange
Market Cap
$8,837,093
Cap Tier
Employees
8
Headquarters
CHICAGO, IL
Listed Since
May 9, 2018
Website
XCUR Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
XCUR Volatility
Exicure, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
